Title: CD10 and Das1: a biomarker study using immunohistochemistry to subtype gastric
intestinal metaplasia
Version: 2 Date: 15 Feb 2022
Reviewer's report:
I read with interest the paper entitled CD10 and Das 1: a biomarker study using
immunohistochemistry to subtype gastric intestinal metaplasia.
I found the paper interesting and the study well conducted. Intestinal metaplasia is an important
step in the evolution of atrophic gastritis versus cancer. Unfortunately, subtyping of complete
and incomplete intestinal metaplasia did not gain universal attention and generally is not
performed for routine assessment of gastric biopsies by histopathologists. I think that new
markers for risk of progression to cancer of intestinal metaplasia merit attention.
I would suggest adding as a limit of the study that the clinical applicability of these markers
seem promising but need to be validated by further studies.
Title: CD10 and Das1: a biomarker study using immunohistochemistry to subtype gastric
intestinal metaplasia
Version: 2 Date: 15 Feb 2022
Reviewer's report:
I read with interest the paper entitled CD10 and Das 1: a biomarker study using
immunohistochemistry to subtype gastric intestinal metaplasia.
I found the paper interesting and the study well conducted. Intestinal metaplasia is an important
step in the evolution of atrophic gastritis versus cancer. Unfortunately, subtyping of complete
and incomplete intestinal metaplasia did not gain universal attention and generally is not
performed for routine assessment of gastric biopsies by histopathologists. I think that new
markers for risk of progression to cancer of intestinal metaplasia merit attention.
I would suggest adding as a limit of the study that the clinical applicability of these markers
seem promising but need to be validated by further studies.
Please review this paper.
user
Title: CD10 and Das1: a biomarker study using immunohistochemistry to subtype gastric
intestinal metaplasia
Version: 2 Date: 15 Feb 2022
Reviewer's report:
I read with interest the paper entitled CD10 and Das 1: a biomarker study using
immunohistochemistry to subtype gastric intestinal metaplasia.
I found the paper interesting and the study well conducted. Intestinal metaplasia is an important
step in the evolution of atrophic gastritis versus cancer. Unfortunately, subtyping of complete
and incomplete intestinal metaplasia did not gain universal attention and generally is not
performed for routine assessment of gastric biopsies by histopathologists. I think that new
markers for risk of progression to cancer of intestinal metaplasia merit attention.
I would suggest adding as a limit of the study that the clinical applicability of these markers
seem promising but need to be validated by further studies.
assistant